摘要
目的探讨乙酰左卡尼汀与甲钴胺对糖尿病周围神经病变(diabetic peripheral neuropathy,DPN)患者疼痛、神经传导速度的影响。方法选择2021年1月至2022年11月我院收治的DPN患者80例,按随机数表法分为观察组(常规治疗+乙酰左卡尼汀)及对照组(常规治疗+甲钴胺),每组40例,均持续治疗3个月。比较两组疼痛缓解、视觉模拟评分法(visual analogue scale,VAS)评分、血糖、正中神经及腓总神经的感觉神经传导速度(sensory nerve conduction velocity,SNCV)、运动神经传导速度(motor nerve conduction velocity,MNCV)变化及不良反应。结果观察组疼痛缓解总有效率高于对照组(P<0.05)。观察组VAS评分低于对照组(P<0.05)。两组正中神经及腓总神经SNCV、MNCV差异无统计学意义(P>0.05)。结论乙酰左卡尼汀与甲钴胺在改善DPN患者神经传导速度方面效果相近,乙酰左卡尼汀在缓解疼痛方面效果更佳,临床应用价值高。
Objective To investigate the effects of acetyl-L-carnitine and mecobalamine on pain,nerve conduction velocity in patients with diabetic peripheral neuropathy(DPN).Methods A total of 80 DPN patients admitted to our hospital from January 2021 to November 2022 were selected and divided into observation group(conventional treatment+acetyl-Lcarnitine)and control group(conventional treatment+mecobalamine)according to random number table method,40 cases in each group,all of which were treated for 3 months.Pain relief,visual analogue scale(VAS)score,blood glucose,sensory nerve conduction velocity(SNCV)of median nerve and common peroneal nerve,motor nerve conduction velocity(MNCV)changes and adverse reactions were compared between the two groups.Results The total effective rate of pain relief in observation group was higher than that in control group(P<0.05).VAS score of observation group was lower than that of control group(P<0.05).There was no significant difference in SNCV and MNCV between the median nerve and common peroneal nerve between the two groups(P>0.05).Conclusion Acetyl-L-carnitine and mecobalamine have similar effects in improving nerve conduction velocity in DPN patients,and acetyl-L-carnitine has better effects in relieving pain,and has high clinical application value.
作者
周仕冲
庄乙君
曾泓铭
曾德利
许文超
ZHOU Shichong;ZHUANG Yijun;ZENG Hongming;ZENG Deli;XU Wenchao(Department of Nephrology,Qionghai People's Hospital,Qionghai 571400,Hainan Province,China;Department of Comprehensive Internal Medicine,the Second Affiliated Hospital of Hainan Medical university,Haikou 570216,Hainan Province,China;Department of Endocrinology,Qionghai People's Hospital,Qionghai 571499,Hainan Province,China;Department of Geriatrics,Qionghai People's Hospital,Qionghai 571499,Hainan Province,China)
出处
《世界临床药物》
CAS
2023年第9期976-980,共5页
World Clinical Drug